Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of Toll-like Receptor (TLR) product candidates primarily in the United States. Based on Dynavax?s proprietary technology platform, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. The company?s product programs are supported by global partnerships with pharmaceutical companies, such as GlaxoSmithKline, AstraZeneca AB, and Novartis Vaccines and Diagnostics, Inc, as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health (NIH). Its product candidates include HEPLISAV, a Phase 3 clinical stage product for the treatment of hepatitis B vaccine; SD-101, a Phase 1b clinical stage product for the treatment of Hepatitis C infection; and DV-601, a Phase 1b clinical stage product for the treatment of Hepatitis B infection. Dynavax Technologies Corporation?s preclinical stage products include Universal Flu vaccine for the treatment of influenza prevention, AZD1419 for the treatment of asthma, and DV1079 for the treatment of autoimmune and inflammatory diseases. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
$1.8475 (06/03/09)
